Drugs / CM310
Trials 36 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07040072 | Oct 2025 → Jun 2027 expected | head and neck squamous cell carcinoma | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06171048 | Apr 2024 → Apr 2025 | — | Keymed Biosciences Co.Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT05702450 | Mar → Jul 2023 | — | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06161090 | Sep 2019 → Jan 2020 | — | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06162507 | Dec 2023 → Jul 2024 | atopic eczema | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 1/2 | NCT04893941 | Jul 2020 → Jan 2021 | atopic eczema | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 216 trials | ||||||
| Phase 2 | NCT07617324 | Jun → Oct 2026 expected | seasonal allergic rhinitis | Chengdu Kangnuoxing Biopharma,Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06883552 | Oct 2025 → Oct 2026 expected | non-small cell lung carcinoma | Sichuan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06525597 | Sep 2024 → Oct 2025 overdue | allergic rhinitis | Keymed Biosciences Co.Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06171074 | Mar 2024 → Mar 2025 | seasonal allergic rhinitis | Keymed Biosciences Co.Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT06116565 | Mar 2024 → Mar 2026 | atopic eczema | Keymed Biosciences Co.Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT06300203 | Mar 2024 → Jun 2026 overdue | seasonal allergic rhinitis | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05908721 | Aug → Dec 2023 | allergic rhinitis | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 2 | NCT05715320 | Mar 2023 → Jul 2024 | atopic eczema | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 2 | NCT05579925 | Oct 2022 → Jul 2023 | atopic eczema | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 2 | NCT05452343 | Aug 2022 → Mar 2024 | — | Keymed Biosciences Co.Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT05470647 | Aug → Sep 2022 | allergic rhinitis | Beijing Tongren Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05186909 | Jan 2022 → Sep 2023 | asthma | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 2 | NCT05131464 | Nov 2021 → Jan 2024 | chronic rhinosinusitis | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 2 | NCT04893707 | Jun 2021 → Feb 2023 | atopic eczema | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 2 | NCT04805398 | Apr 2021 → Mar 2022 | chronic rhinosinusitis, nasal cavity polyp | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 2 | NCT04805411 | Feb → Nov 2021 | atopic eczema | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06547333 | Sep 2024 → Apr 2032 expected | chronic obstructive pulmonary disease | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05761028 | Apr 2023 → May 2032 expected | asthma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT07678931 | Aug → Dec 2026 expected | seasonal allergic rhinitis | Chengdu Kangnuoxing Biopharma,Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07210554 | Nov 2025 → Mar 2028 expected | bullous pemphigoid | Chengdu Kangnuoxing Biopharma,Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06495229 | Aug 2024 → Aug 2026 overdue | atopic eczema | Keymed Biosciences Co.Ltd | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06424470 | Jun 2024 → Feb 2026 | prurigo nodularis | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 3 | NCT06277765 | Mar 2024 → Jan 2025 | atopic eczema | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 3 | NCT05908032 | Aug → Dec 2023 | seasonal allergic rhinitis | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 3 | NCT05265923 | Apr 2022 → Oct 2023 | atopic eczema | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06801353 | Feb → Dec 2025 overdue | chronic rhinosinusitis | Beijing Tongren Hospital | Not yet recruiting | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07616609 | Jun 2026 → Dec 2028 expected | chronic rhinosinusitis | Beijing Tongren Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07240376 | Nov 2025 → Dec 2026 expected | rhinitis | Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| — | NCT07143864 | Sep 2025 → Dec 2026 expected | primary cutaneous amyloidosis | First Affiliated Hospital of Chongqing Medical University | Not yet recruiting | No outcome recorded |
| — | NCT05728684 | Feb 2023 → Feb 2024 | immunoglobulin G4-related sclerosing disease | Beijing Friendship Hospital | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05436275 Comparator | Aug 2022 → Jun 2024 | chronic rhinosinusitis | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 41 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CM310 | “efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): an investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial.” PMID 38356731 ↗ Feb 202425“The goal of this clinical trial is to learn if Stapokibart (CM310) works to treat Non-Allergic Rhinitis with Eosinophilia Syndrome (NARES) in adults.” NCT07240376 ↗ “Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis” NCT06300203 ↗ |
| Known as | Stapokibart | “BACKGROUND: Stapokibart/CM310, a humanized monoclonal antibody targeting the interleukin-4 receptor α chain, has shown promising treatment benefits in patients with...” PMID 39080181 ↗ Jul 202415“efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): an investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial.” PMID 38356731 ↗ Feb 2024 “Stapokibart is a novel anti-interleukin-4 receptor α (IL-4Rα) monoclonal antibody approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD).” PMID 41284735 ↗ Mar 2026 “Stapokibart, a novel humanized monoclonal antibody that targets interleukin-4Rα, has been approved in China for the treatment of adults with moderate-to-severe AD.” PMID 41697953 ↗ May 2026 “An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer” NCT06883552 ↗ “Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis.” PMID 38833140 ↗ Jun 2024 |
| Known as | Stapokibart Injection | “Stapokibart Injection in Combination with Tislelizumab Injection in Patients with NSCLC” NCT06883552 ↗ |
| Action | Inhibit | “inhibits IL-4 and IL-13 signaling” PMID 37483544 ↗ Jul 2023 |
| Modality | Monoclonal antibody | “CM310, a humanised anti-interleukin (IL)-4 receptor alpha monoclonal antibody” PMID 37483544 ↗ Jul 2023 |
| Route | Subcutaneous | “receive subcutaneously either CM310 (300 mg) or placebo” PMID 37483544 ↗ Jul 2023 |
| Target | IL4R | “CM310, a humanised anti-interleukin (IL)-4 receptor alpha monoclonal antibody” PMID 37483544 ↗ Jul 2023 |